



For immediate release

Seinäjoki, Finland 29.08.2024

FLAGGING OF PURCHASE OF SHARES AND MAJOR CHANGE OF HOLDINGS BY PMDR IN EEVIA HEALTH PLC

Betulum AS (“Betulum”), a close associate of Martin Bjørklund, the chairman of the board of Eevia Health Plc (“Eevia” or “The Company”), has purchased 1,000,000 shares in Eevia Health Plc.

Betulum purchased 1,000,000 shares in Eevia Health Plc through the subscription of new shares in the recent Rights issue in the Company, completed in July. The Company delivered the shares to Betulum on 26 August 2024. The price for the shares Betulum subscribed for was SEK 0.60 per share, in line with the terms of the Rights issue for subscriptions in Sweden. Hence, the 1,000,000 shares were purchased for a sum of SEK 600,000.

Betulum owned 3,653,700 shares before the purchase, constituting 10.2% of the outstanding shares before the Rights issue (35,713,884).

Betulum now owns 4,653,700 shares. The Rights issue was for 28,641,604 shares, and the total outstanding shares increased to 64,355,488 shares. Hence, Betulum's new holding now equals 7,2% of the Company's current outstanding shares. Due to the dilution from the Rights issue, his shareholding fell below the 10% level of the new outstanding total shares despite the purchase of shares.

Betulum was also awarded 250,000 Warrants TO1 as part of the rights issue subscription. The subscription period is 18 August 2025 – 29 August 2025, and the share subscription price is determined by the volume-weighted average price of the Company's share on Spotlight between 31 July 2025 and 13 August 2025, with a 25 percent discount applied.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc

Email: stein.ulve@eeviahealth.com or investor@eeviahealth.com

Telephone: +358 400 22 5967



INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.

Eevia Health manufactures 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga, and pine bark, are wild-harvested sustainably.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. In June 2021, Eevia listed its shares on the Spotlight Stock Market in Sweden under the short name (ticker) [EEVIA](#).

To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.